Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
SELLAS Life Sciences Group, Inc. (SLS) had Stock-Based Compensation of $1.01M for the most recently reported fiscal quarter, ending 2025-06-30.
Income Statement Financials | |
-- |
|
$-6.60M |
|
-- |
|
-- |
|
$6.87M |
|
$-6.87M |
|
$0.27M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-6.87M |
|
$-6.87M |
|
98.56M |
|
98.56M |
|
$-0.07 |
|
$-0.07 |
|
Balance Sheet Financials | |
$29.45M |
|
-- |
|
$2.86M |
|
$32.30M |
|
$6.00M |
|
-- |
|
$0.16M |
|
$6.16M |
|
$26.15M |
|
$24.23M |
|
$26.15M |
|
100.37M |
|
Cash Flow Statement Financials | |
$-16.40M |
|
-- |
|
$27.81M |
|
$13.99M |
|
$25.40M |
|
$11.41M |
|
Stock-Based Compensation |
$1.01M |
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
4.91 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.40M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.24% |
|
-27.24% |
|
-20.43% |
|
-25.24% |
|
$0.26 |
|
$-0.17 |
|
$-0.17 |